Home KEYTRUDA (pembrolizumab) is First Medicine to be Made Available to Patients Through U.K. Early Access to Medicines Scheme (EAMS) for Advanced Melanoma
 

Keywords :   


KEYTRUDA (pembrolizumab) is First Medicine to be Made Available to Patients Through U.K. Early Access to Medicines Scheme (EAMS) for Advanced Melanoma

2015-03-11 01:01:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. EAMS Aims to Give U.K. Patients Access to Promising, Innovative Treatments Prior to European License KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the companys anti-PD-1 therapy, pembrolizumab, which is marketed in the U.S. under the name KEYTRUDA, is the first treatment to be accepted under the U.K.s new Early Access to Medicines Scheme (EAMS). Pembrolizumab was accepted under the scheme for the treatment of advanced melanoma based on the significance of the early study findings and unmet medical need. Language: English Contact: MerckMedia Contacts:Pam Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orInvestor Contacts:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: to for made advanced

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
26.11JELEEBOX
26.11
26.11222CB
26.11BOSS ( ) BB-1X Bass Driver
26.1112010 re0827-141
26.11
26.11 2021 EDITION
26.11DVD
More »